Cost-effectiveness of PCSK9 Inhibitors for Heterozygous FH or ASCVD
JAMA Author Interviews - Ein Podcast von JAMA Network
Interview with Dhruv S. Kazi, MD, MSc, MS, author of Cost-effectiveness of PCSK9 Inhibitor Therapy in Patients With Heterozygous Familial Hypercholesterolemia or Atherosclerotic Cardiovascular Disease
